Mayo Clinic Q & amp;A podcast: Bladder cancer patients require ongoing surveillance
Bladder cancer is a common type of cancer that begins in the cells of the bladder, a hollow muscular organ in the lower abdomen that stores urine. Bladder cancer signs and symptoms can include blood in the urine, frequent or painful urination, and back pain. "The vast majority of bladder cancer patients are diagnosed with cancer that's not [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 17, 2021 Category: Databases & Libraries Source Type: news
Consumer Health: Bladder cancer awareness
May is Bladder Cancer Awareness Month, which makes this a good time to learn more about bladder cancer. Bladder cancer is one of the most common cancers. Nearly 84,000 new cases will be diagnosed in the U.S. in 2021, according to the American Cancer Society. Bladder cancer occurs in men more frequently than in women, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 13, 2021 Category: Databases & Libraries Source Type: news
How Long Will You Live if You Have Bladder Cancer?
Title: How Long Will You Live if You Have Bladder Cancer?Category: Diseases and ConditionsCreated: 5/6/2021 12:00:00 AMLast Editorial Review: 5/6/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 6, 2021 Category: Cancer & Oncology Source Type: news
What Are the Different Stages of Bladder Cancer?
Title: What Are the Different Stages of Bladder Cancer?Category: Diseases and ConditionsCreated: 4/30/2021 12:00:00 AMLast Editorial Review: 4/30/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 30, 2021 Category: Cancer & Oncology Source Type: news
To Stay: Two More Cancer Indications With'Dangling Approvals'To Stay: Two More Cancer Indications With'Dangling Approvals '
On the second day of a historic meeting, FDA advisers voted to keep the accelerated approvals for two immunotherapies for use in bladder cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for previously untreated metastatic bladder cancer
Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favour of maintaining accelerated approval of Tecentriq® (atezolizumab) for the treatment of adults with locally advanced or metastatic urothel ial carcinoma (mUC, bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumours express high levels of PD-L1 (PD-L1–stained tumour-infiltrating immune cells covering ≥5 percent of the tumour area) as determined by an FDA-approved test or are not eligible for any platinum...
Source: Roche Investor Update - April 28, 2021 Category: Pharmaceuticals Source Type: news
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for previously untreated metastatic bladder cancer
Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favour of maintaining accelerated approval of Tecentriq® (atezolizumab) for the treatment of adults with locally advanced or metastatic urothel ial carcinoma (mUC, bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumours express high levels of PD-L1 (PD-L1–stained tumour-infiltrating immune cells covering ≥5 percent of the tumour area) as determined by an FDA-approved test or are not eligible for any platinum...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news
Male bladder cancer vulnerability could lead to a new treatment approach
(University of California - Davis Health) UC Davis Comprehensive Cancer Center researchers found that targeting androgen receptors - a type of protein that is crucial for the function of testosterone - may destroy cancer cells. Focusing on this protein variant common in malignant bladder tumor cells may serve as a new avenue for treating bladder cancer in men. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 28, 2021 Category: International Medicine & Public Health Source Type: news
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - April 27, 2021 Category: Pharmaceuticals Source Type: news
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Investor Update - April 27, 2021 Category: Pharmaceuticals Source Type: news
What Are the 5 Warning Signs of Bladder Cancer?
Title: What Are the 5 Warning Signs of Bladder Cancer?Category: Diseases and ConditionsCreated: 4/22/2021 12:00:00 AMLast Editorial Review: 4/22/2021 12:00:00 AM (Source: MedicineNet Hearing General)
Source: MedicineNet Hearing General - April 22, 2021 Category: Audiology Source Type: news
Therapeutic Cancer Vaccine Shows Promise Against Multiple Tumor Types
TUESDAY, April 13, 2021 -- Marc Baum went through all the usual steps to treat his bladder cancer -- a couple of surgeries, radiation therapy and chemotherapy, all in a three-month period.
But doctors hope that an extra step -- an experimental... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 13, 2021 Category: General Medicine Source Type: news
Urinary Incontinence Surgery Won't Raise a Woman's Cancer Risk
NDAY, April 12, 2021 -- Women face no increased risk of pelvic cancer -- tumors of the bladder, cervix and ovaries -- if they have surgery to treat stress urinary incontinence (SUI), a new study finds.
Concerns about possible complications and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 12, 2021 Category: General Medicine Source Type: news
Personalized cancer vaccine is safe, shows potential benefit against cancer
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clinical trial presented during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, held April 10-15. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2021 Category: Cancer & Oncology Source Type: news
Genes and immune cells predict immunotherapy success in bladder cancer
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai. In a study published in Clinical Cancer Research, the team uncovered gene signatures representing adaptive immunity and pro-tumorigenic inflammation that were responsible for sensitivity or resistance to immune checkpoint inhibitors, drugs that help the body's immune system recognize and attack cancerous cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 9, 2021 Category: Cancer & Oncology Source Type: news
